These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477 [TBL] [Abstract][Full Text] [Related]
9. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637 [TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Human and Murine Dermal Fibroblasts to Herpes Simplex Virus 1 in the Absence and Presence of Extracellular Matrix. Wirtz L; De La Cruz NC; Möckel M; Knebel-Mörsdorf D J Virol; 2022 Feb; 96(4):e0206821. PubMed ID: 34908440 [TBL] [Abstract][Full Text] [Related]
11. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Aghi M; Rabkin SD; Martuza RL Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Lee CY; Rennie PS; Jia WW Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871 [TBL] [Abstract][Full Text] [Related]
13. Role of tumor invasiveness, the extracellular matrix, and chromatin sequestration in the susceptibility of uveal melanoma to herpes simplex virus type 1. Valyi-Nagy K; Folberg R; Valyi-Nagy T; Maniotis AJ Exp Eye Res; 2007 May; 84(5):991-1000. PubMed ID: 17386925 [TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus 1 (HSV-1) for cancer treatment. Shen Y; Nemunaitis J Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059 [TBL] [Abstract][Full Text] [Related]
15. Restrictions that control herpes simplex virus type 1 infection in mouse brain ex vivo. Cohen M; Braun E; Tsalenchuck Y; Panet A; Steiner I J Gen Virol; 2011 Oct; 92(Pt 10):2383-2393. PubMed ID: 21697348 [TBL] [Abstract][Full Text] [Related]
16. A novel system to study adenovirus tropism to normal and malignant colon tissues. Kolodkin-Gal D; Zamir G; Pikarski E; Pikarski A; Shimony N; Wu H; Haviv YS; Panet A Virology; 2007 Jan; 357(1):91-101. PubMed ID: 16962151 [TBL] [Abstract][Full Text] [Related]
17. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures. Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986 [TBL] [Abstract][Full Text] [Related]
18. Tumour-specific triple-regulated oncolytic herpes virus to target glioma. Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093 [TBL] [Abstract][Full Text] [Related]